Background: Deep learning (DL)-based models have demonstrated an ability to automatically diagnose clinically significant prostate cancer (PCa) on MRI scans and are regularly reported to approach expert performance. The aim of this work was to systematically review the literature comparing deep learning (DL) systems to radiologists in order to evaluate the comparative performance of current state-of-the-art deep learning models and radiologists.
Methods: This systematic review was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Studies investigating DL models for diagnosing clinically significant (cs) PCa on MRI were included. The quality and risk of bias of each study were assessed using the checklist for AI in medical imaging (CLAIM) and QUADAS-2, respectively. Patient level and lesion-based diagnostic performance were separately evaluated by comparing the sensitivity achieved by DL and radiologists at an identical specificity and the false positives per patient, respectively.
Results: The final selection consisted of eight studies with a combined 7337 patients. The median study quality with CLAIM was 74.1% (IQR: 70.6-77.6). DL achieved an identical patient-level performance to the radiologists for PI-RADS ≥ 3 (both 97.7%, SD = 2.1%). DL had a lower sensitivity for PI-RADS ≥ 4 (84.2% vs. 88.8%, = 0.43). The sensitivity of DL for lesion localization was also between 2% and 12.5% lower than that of the radiologists.
Conclusions: DL models for the diagnosis of csPCa on MRI appear to approach the performance of experts but currently have a lower sensitivity compared to experienced radiologists. There is a need for studies with larger datasets and for validation on external data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605624 | PMC |
http://dx.doi.org/10.3390/life12101490 | DOI Listing |
Appl Neuropsychol Adult
January 2025
Faculty Xavier Institute of Engineering, Mahim, India.
In the fields of engineering, science, technology, and medicine, artificial intelligence (AI) has made significant advancements. In particular, the application of AI techniques in medicine, such as machine learning (ML) and deep learning (DL), is rapidly growing and offers great potential for aiding physicians in the early diagnosis of illnesses. Depression, one of the most prevalent and debilitating mental illnesses, is projected to become the leading cause of disability worldwide by 2040.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Department of Computer Science and Software Engineering, United Arab Emirates University, Al Ain, United Arab Emirates.
Background: Neuroimaging segmentation is increasingly important for diagnosing and planning treatments for neurological diseases. Manual segmentation is time-consuming, apart from being prone to human error and variability. Transformers are a promising deep learning approach for automated medical image segmentation.
View Article and Find Full Text PDFJMIR Form Res
January 2025
Department of Public Health, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, 470-1192, Japan, 81 562-93-2476, 81 562-93-3079.
Background: Estimating the prevalence of schizophrenia in the general population remains a challenge worldwide, as well as in Japan. Few studies have estimated schizophrenia prevalence in the Japanese population and have often relied on reports from hospitals and self-reported physician diagnoses or typical schizophrenia symptoms. These approaches are likely to underestimate the true prevalence owing to stigma, poor insight, or lack of access to health care among respondents.
View Article and Find Full Text PDFBrief Bioinform
November 2024
Center for Artificial Intelligence Research, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Pathway analysis plays a critical role in bioinformatics, enabling researchers to identify biological pathways associated with various conditions by analyzing gene expression data. However, the rise of large, multi-center datasets has highlighted limitations in traditional methods like Over-Representation Analysis (ORA) and Functional Class Scoring (FCS), which struggle with low signal-to-noise ratios (SNR) and large sample sizes. To tackle these challenges, we use a deep learning-based classification method, Gene PointNet, and a novel $P$-value computation approach leveraging the confusion matrix to address pathway analysis tasks.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!